The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

Non-alcoholic fatty liver disease (NAFLD), which is strongly associated with metabolic syndrome, is increasingly a major cause of hepatic disorder. Dipeptidyl peptidase (DPP)-4 inhibitors, anti-diabetic agents, are expected to be effective for the treatment of NAFLD. In the present study, we establi...

Full description

Bibliographic Details
Main Authors: Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:International Journal of Molecular Sciences
Subjects:
AMPK
DPP-4 inhibitor
lipogenesis
non-alcoholic fatty liver disease
NAFLD
SREBP1c
teneligliptin
Online Access:http://www.mdpi.com/1422-0067/16/12/26156

Similar Items

Similar Items